All Updates

All Updates

icon
Filter
Funding
Metagenomi raises USD 100 million in Series B extension
Human Gene Editing
Jan 5, 2023
This week:
Product updates
Meta introduces Meta Credits digital currency for Horizon Worlds
Metaverse Platforms
Today
Product updates
Liquid AI launches STAR framework for AI model architecture optimization
Foundation Models
Today
Funding
9fin raises USD 50 million in Series B funding to expand US operations
Capital Markets Tech
Yesterday
Partnerships
Shastic partners with MeridianLink to provide AI workflow automation for financial institutions
Workflow Automation Platforms
Yesterday
Funding
KisoJi Biotechnology raises CAD 41 million to develop oncology candidate
AI Drug Discovery
Yesterday
M&A
Deel acquires UK money transfer startup Atlantic Money for undisclosed sum
Remote Work Infrastructure
Yesterday
Funding
Acorai raises EUR 4.2 million in funding to advance clinical studies
Next-gen Medical Devices
Yesterday
Product updates
Bosch announces Light Drive, an AR solution for all-day smart glasses
Extended Reality
Yesterday
Partnerships
Product updates
Vuzix expands OSHA collaboration; launches upgraded M400 AR smart glasses
Extended Reality
Yesterday
Product updates
StrikerVR launches pre-orders for consumer-facing Mavrik haptic VR gun
Extended Reality
Yesterday
Human Gene Editing

Human Gene Editing

Jan 5, 2023

Metagenomi raises USD 100 million in Series B extension

Funding

  • California-based gene editing biotechnology company Metagenomi has raised an additional USD 100 million in a Series B extension.This round was co-led by Novo Holdings A/S, Catalio Capital Management, and SymBiosis, with participation from new and existing investors, including Leaps by Bayer and Moderna, bringing the total funds raised by the company to USD 457 million. Furthermore, Novo Ventures’ Partner Ray Camahort will join the company’s board of directors as an observer. 

  • The new funds will be used to advance its lead programs through preclinical developments and into clinical proof-of-concept studies. Furthermore, the company plans to expand its targets for preclinical proof-of-concept studies using its proprietary discovery engine.

Contact us

Gain access to all industry hubs, market maps, research tools, and more
Get a demo
arrow
menuarrow

By using this site, you agree to allow SPEEDA Edge and our partners to use cookies for analytics and personalization. Visit our privacy policy for more information about our data collection practices.